Astrana Health Updates Investor Presentation via Regulation FD Disclosure

Astrana Health ( (ASTH) ) just unveiled an update.

On May 12, 2026, Astrana Health updated its corporate investor presentation, which it plans to use at upcoming conferences and meetings, and furnished the new slide deck via a Form 8-K. The company emphasized that the materials are furnished rather than filed under U.S. securities laws, signaling they are not deemed part of its formal filings or subject to associated liability standards for material information, a distinction relevant for investors and regulators.

The most recent analyst rating on (ASTH) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on Astrana Health stock, see the ASTH Stock Forecast page.

Spark’s Take on ASTH Stock

According to Spark, TipRanks’ AI Analyst, ASTH is a Neutral.

The score is driven primarily by solid financial performance (notably strong and growing free cash flow and improved leverage) and a positive earnings call featuring reaffirmed guidance and continued deleveraging. Offsetting these positives are sharply compressed profitability/returns and an extended technical setup (RSI/Stoch elevated), while valuation appears fair rather than clearly cheap.

To see Spark’s full report on ASTH stock, click here.

More about Astrana Health

Astrana Health, Inc. operates in the healthcare services industry, focusing on managing risk-based arrangements across Medicare, Medicaid, commercial and other third-party payors. The company’s revenue model includes full- and partial-risk capitation, risk pool settlements and incentives, management fee income and fee-for-service revenue, reflecting a diversified payer and contract mix.

Average Trading Volume: 490,533

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.95B

For a thorough assessment of ASTH stock, go to TipRanks’ Stock Analysis page.